These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 36592175)

  • 1. Urinary biomarkers for bladder cancer diagnosis and NMIBC follow-up: a systematic review.
    Soorojebally Y; Neuzillet Y; Roumiguié M; Lamy PJ; Allory Y; Descotes F; Ferlicot S; Kassab-Chahmi D; Oudard S; Rébillard X; Roy C; Lebret T; Rouprêt M; Audenet F
    World J Urol; 2023 Feb; 41(2):345-359. PubMed ID: 36592175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel urinary biomarkers ADXBLADDER and bladder EpiCheck for diagnostics of bladder cancer: A review.
    Wolfs JRE; Hermans TJN; Koldewijn EL; van de Kerkhof D
    Urol Oncol; 2021 Mar; 39(3):161-170. PubMed ID: 33376063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reflex fluorescence in situ hybridization assay for suspicious urinary cytology in patients with bladder cancer with negative surveillance cystoscopy.
    Kim PH; Sukhu R; Cordon BH; Sfakianos JP; Sjoberg DD; Hakimi AA; Dalbagni G; Lin O; Herr HW
    BJU Int; 2014 Sep; 114(3):354-9. PubMed ID: 24128299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.
    Kassouf W; Traboulsi SL; Schmitz-Dräger B; Palou J; Witjes JA; van Rhijn BW; Grossman HB; Kiemeney LA; Goebell PJ; Kamat AM
    Urol Oncol; 2016 Oct; 34(10):460-8. PubMed ID: 27368880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Photodynamic cystoscopy for bladder cancer diagnosis and for NMIBC follow-up: An overview of systematic reviews and meta-analyses.
    Soorojebally Y; Neuzillet Y; Lebret T; Allory Y; Descotes F; Ferlicot S; Kassab-Chahmi D; Lamy PJ; Oudard S; Rébillard X; Roy C; Roumiguié M; Rouprêt M; Audenet F
    Prog Urol; 2023 May; 33(6):307-318. PubMed ID: 37088584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of Xpert Bladder Cancer Monitor test performance for the detection of recurrence during non-muscle invasive bladder cancer follow-up.
    Cancel-Tassin G; Roupret M; Pinar U; Gaffory C; Vanie F; Ondet V; Compérat E; Cussenot O
    World J Urol; 2021 Sep; 39(9):3329-3335. PubMed ID: 33770241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis.
    Laukhtina E; Shim SR; Mori K; D'Andrea D; Soria F; Rajwa P; Mostafaei H; Compérat E; Cimadamore A; Moschini M; Teoh JY; Enikeev D; Xylinas E; Lotan Y; Palou J; Gontero P; Babjuk M; Witjes JA; Kamat AM; Roupret M; Shariat SF; Pradere B;
    Eur Urol Oncol; 2021 Dec; 4(6):927-942. PubMed ID: 34753702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the performances of the ADXBLADDER test and urinary cytology in the follow-up of non-muscle-invasive bladder cancer: a blinded prospective multicentric study.
    Gontero P; Montanari E; Roupret M; Longo F; Stockley J; Kennedy A; Rodriguez O; McCracken SRC; Dudderidge T; Sieverink C; Vanié F; Allasia M; Witjes JA; Sylvester R; Colombel M; Palou J
    BJU Int; 2021 Feb; 127(2):198-204. PubMed ID: 32745350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study.
    Pichler R; Tulchiner G; Fritz J; Schaefer G; Horninger W; Heidegger I
    Int J Med Sci; 2017; 14(9):811-819. PubMed ID: 28824318
    [No Abstract]   [Full Text] [Related]  

  • 10. [The use of NMP22 Bladder-Chek for the diagnosis and follow-up bladder cancer].
    Gonzalo Rodríguez V; Sanz Justo L; de Miguel Santamaría I; Martínez de Iturrate J; Fernández del Busto E
    Arch Esp Urol; 2008 Apr; 61(3):377-84. PubMed ID: 18581675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal follow-up and performance validation of an mRNA-based urine test (Xpert
    Cowan B; Klein E; Jansz K; Westenfelder K; Bradford T; Peterson C; Scherr D; Karsh LI; Egerdie B; Witjes A; Trainer A; Harris R; Goldfarb B; Flax S; Kroeger R; Boyd B; Liao J; Patel S; Bridge J; Reuter V; Quigley N; Brown S; Zhao S; Satya M; Bates M; Simon IM; Campbell S; Lotan Y
    BJU Int; 2021 Dec; 128(6):713-721. PubMed ID: 33793062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic relevance of positive urine markers in patients with negative cystoscopy during surveillance of bladder cancer.
    Todenhöfer T; Hennenlotter J; Guttenberg P; Mohrhardt S; Kuehs U; Esser M; Aufderklamm S; Bier S; Harland N; Rausch S; Gakis G; Stenzl A; Schwentner C
    BMC Cancer; 2015 Mar; 15():155. PubMed ID: 25884545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of urine markers, white light cystoscopy and fluorescence cystoscopy in recurrence, progression and follow-up of non-muscle invasive bladder cancer.
    Karaoglu I; van der Heijden AG; Witjes JA
    World J Urol; 2014 Jun; 32(3):651-9. PubMed ID: 24166285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urine Cytology Rarely Escalates Clinical Management in the Surveillance of Non-muscle-Invasive Bladder Cancer.
    Feiertag N; Barry E; Abramson M; Park JY; Kovac E; Aboumohamed A; Watts K; Sankin A
    Clin Genitourin Cancer; 2023 Apr; 21(2):258-264. PubMed ID: 36621462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance.
    Pichler R; Fritz J; Tulchiner G; Klinglmair G; Soleiman A; Horninger W; Klocker H; Heidegger I
    BJU Int; 2018 Jan; 121(1):29-37. PubMed ID: 28941000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implications of the COVID19 pandemic on the need and timing of second transurethral bladder tumour resection in high-grade non-muscle invasive bladder cancer.
    Vanneste M; van der Heij B; Christiaansen CE; Berendsen CL; Driessen EJM; Bruins HM
    World J Urol; 2023 Aug; 41(8):2173-2178. PubMed ID: 37328699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
    Kumar A; Kumar R; Gupta NP
    Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma.
    Lotan Y; OʼSullivan P; Raman JD; Shariat SF; Kavalieris L; Frampton C; Guilford P; Luxmanan C; Suttie J; Crist H; Scherr D; Asroff S; Goldfischer E; Thill J; Darling D
    Urol Oncol; 2017 Aug; 35(8):531.e15-531.e22. PubMed ID: 28366272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer.
    Mowatt G; Zhu S; Kilonzo M; Boachie C; Fraser C; Griffiths TR; N'Dow J; Nabi G; Cook J; Vale L
    Health Technol Assess; 2010 Jan; 14(4):1-331, iii-iv. PubMed ID: 20082749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients with a negative cystoscopy and negative Nmp22® Bladderchek® test are at low risk of missed transitional cell carcinoma of the bladder: a prospective evaluation.
    Terrell JD; Elias KJ; Sagalowsky AI; Lotan Y
    Int Braz J Urol; 2011; 37(6):706-11. PubMed ID: 22234001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.